Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced interim Phase II data for their anti-TIGIT biologic domvanalimab in combination with the anti-PD-1 drug zimberelimab. The treatment is being investigated for locally advanced unresectable or metastatic upper gastrointestinal cancers. The study, which has a median time on treatment of 49.4 weeks, reported a median progression-free survival (PFS) of 12.9 months, a confirmed objective response rate (ORR) of 58.5%, and a median duration of response (DOR) of 12.4 months.
The positive results were consistent across both PD-L1-high and PD-L1-low subgroups. Moreover, the safety profile of the drug combination aligns with the known safety profiles of each individual drug.
The U.S.-based partners have already progressed the treatment into the late stages of development, with enrollment for the new study anticipated to complete this year.- Flcube.com
